Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 23;10(11):1669.
doi: 10.3390/antiox10111669.

Are Antioxidants Useful in Preventing the Progression of Chronic Kidney Disease?

Alfredo G Casanova  1   2   3   4   5 , Francisco J López-Hernández  1   3   4   5   6 , Laura Vicente-Vicente  1   2   3   4   5 , Ana I Morales  1   2   3   4   5   6
Affiliations
Review

Are Antioxidants Useful in Preventing the Progression of Chronic Kidney Disease?

Alfredo G Casanova et al. Antioxidants (Basel). .

Abstract

Chronic kidney disease (CKD) is a progressive impairment of renal function for more than three months that affects 15% of the adult population. Because oxidative stress is involved in its pathogenesis, antioxidants are under study for the prophylaxis of CKD progression. The objective of this work was to meta-analyze the efficacy of antioxidant therapy in CKD patients and to identify the most effective candidate antioxidants. Our meta-analysis showed that, despite being quite heterogeneous, overall antioxidant therapy apparently reduced CKD progression. Pentoxifylline and bardoxolone methyl demonstrated a robust and statistically significant protection, while other products showed a favorable but non-significant tendency, due to a high interindividual variability. Off-target (i.e., antioxidant-independent) effects, such as body weight reduction and heart failure-associated blood dilution, might totally or partially explain the protection provided by effective antioxidants. This potential pleiotropy introduces uncertainty on the role of oxidative stress in CKD progression and on antioxidant therapy in its prevention, which needs to be further investigated. Independently, identification of factors determining the nephroprotective effect of each candidate on each patient is thus necessary for a prospectively personalized antioxidant therapy. Finally, pentoxifylline should be further explored for the prophylaxis of CKD progression.

Keywords: antioxidants; bardoxolone methyl; chronic kidney disease; meta-analysis; nephroprotection; pentoxifylline.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study search and selection flow diagram made in accordance with the PRISMA guidelines.
Figure 2
Figure 2
Forest plots in which the nephroprotection of the different treatments tested against CKD is compared to the placebo/control groups evaluated by means of different biomarkers of renal function. The effect size is measured as Hedges’ g ± 95% CI. CC: cyanocobalamin; CI: confidence interval; Crpl: plasma creatinine; DHA: docosahexaenoic acid; eGFR: estimated glomerular filtration rate; EPA: eicosapentaenoic acid; FA: folic acid; NAC: N-acetylcysteine; PH: pyridoxine hydrochloride; w: week.
Figure 3
Figure 3
Funnel plots and asymmetry tests corresponding to the meta-analysis of the parameters eGFR (a), Crpl (b), and albuminuria (c). The effect size is measured as Hedges’ g ± 95% CI. CES: combined effect size; CI: confidence interval.
Figure 4
Figure 4
Influence of lifestyle on oxidative stress. On the left side, the factors that favor the oxidative state are listed, while on the right side are those that favor antioxidant activity.
See this image and copyright information in PMC

References

    1. Carriazo S., Ortiz A. European East-West Divide in Kidney Disease: The Need to Understand the Drivers of Chronic Kidney Disease Outcomes. Clin. Kidney J. 2021;14:1–4. doi: 10.1093/ckj/sfaa217. - DOI - PMC - PubMed
    1. Levey A.S., de Jong P.E., Coresh J., Nahas M.E.L., Astor B.C., Matsushita K., Gansevoort R.T., Kasiske B.L., Eckardt K.-U. The Definition, Classification, and Prognosis of Chronic Kidney Disease: A KDIGO Controversies Conference Report. Kidney Int. 2011;80:17–28. doi: 10.1038/ki.2010.483. - DOI - PubMed
    1. Choi B., Kang K.-S., Kwak M.-K. Effect of Redox Modulating NRF2 Activators on Chronic Kidney Disease. Molecules. 2014;19:12727–12759. doi: 10.3390/molecules190812727. - DOI - PMC - PubMed
    1. Bikbov B., Purcell C.A., Levey A.S., Smith M., Abdoli A., Abebe M., Adebayo O.M., Afarideh M., Agarwal S.K., Agudelo-Botero M., et al. Global, Regional, and National Burden of Chronic Kidney Disease, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–733. doi: 10.1016/S0140-6736(20)30045-3. - DOI - PMC - PubMed
    1. Chronic Kidney Disease Basics|Chronic Kidney Disease Initiative|CDC. [(accessed on 8 April 2021)]; Available online: https://www.cdc.gov/kidneydisease/basics.html.

LinkOut - more resources